Healthcare / BiotechnologyTaiwan
$60.70
+0.40 (+0.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $151.2M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.2B
P/E
27.5x
↑EV/EBITDA
12.1x
↓ROE
9.7%
↑Gross Margin
54.1%
↑Debt/Equity
0.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.9%
FCF CAGR
-19.6%
FCF margin
7.3%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.06B · net income $190.2M · FCF $151.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.06B | $2.06B | $2.03B | $1.88B | $2.40B |
| Net Income | $190.2M | $190.2M | $124.5M | $77.2M | $182.3M |
| EBITDA | $446.8M | $446.8M | $396.9M | $350.5M | $504.5M |
| EPS | — | — | 1.45 | 0.90 | 2.12 |
| Gross Margin | 54.1% | 54.1% | 52.7% | 51.8% | 55.0% |
| Operating Margin | 15.0% | 15.0% | 10.6% | 8.3% | 17.3% |
| Net Margin | 9.2% | 9.2% | 6.1% | 4.1% | 7.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.33 | 0.33 | 0.37 | 0.38 | 0.24 |
| Current Ratio | 1.28 | 1.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $151.2M | $151.2M | $165.5M | $-3.8M | $291.2M |
| Returns | |||||
| ROE | 9.7% | 9.7% | 6.5% | 4.0% | 9.1% |
| Valuation | |||||
| P/E | 27.47 | 27.47 | 57.52 | 125.00 | 80.90 |
| EV/EBITDA | 12.07 | 12.07 | 18.40 | 28.09 | 29.21 |
| P/B | 2.66 | 2.66 | 3.72 | 5.05 | 7.33 |
| Growth & Yield | |||||
| Revenue Growth | 1.7% | 1.7% | 7.9% | -21.5% | — |
| EPS Growth | — | — | 61.1% | -57.5% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.8%
Start / end P/E
n/dx → n/dx
EPS bridge
1.45 → n/d
Residual
-20.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.